Best Life Sciences Companies in Australia
The 688 best Life Sciences companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Mesoblast.
Measured by disclosed equity funding, these 688 Life Sciences companies in Australia represent $4.2 billion in committed capital, and that number alone tells you this is a serious innovation ecosystem, not a peripheral one. Mesoblast anchors the top of the directory at $980 million raised, a figure that dwarfs every other name on the list. Kazia Therapeutics follows at $86 million. The gap between those two and the rest of the field is steep, which is how concentrated capital tends to work in biotech. Global life sciences is tracking a ~10.2% CAGR on a base that reflects decades of compounding demand from an aging population and accelerating R&D commercialisation.
So what's actually moving right now? I'd point to the deal activity as much as the funding tallies. The sector has one unicorn among the 688 tracked here, and the most active backers, Artesian, Brandon Capital, and the Medical Research Commercialisation Fund, are institutions with genuine conviction rather than tourist capital. A TPG-backed life sciences IPO filing signals that public markets appetite for the sector remains real. Smaller players like Micro-X at $47 million and CurveBeam AI at $25 million show the funding ladder here has real rungs below the headline names. The directory gives you the full picture.
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Australia
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Mesoblast Biotherapeutics derived from proprietary adult stem cell-based technologies | $980M | 17 mo ago | 83 | — | DrupalPHPAmazon Web Services+19 | 25 signals ▲178% Acquisition · Earnings · Funding | 70 patents Regenerative cell therapies using adult multipotent stem cells for neurological and musculoskeletal disorders | — |
| 2 | Novotech 🦄 Provider of clinical research services across all trial phases and therapeutic areas 72Funding top 25%Fin. health top 26%Product top 26%Innovation top 34% All 10 signals ▾Fundingtop 25% Fin. healthtop 26% Producttop 26% Innovationtop 34% Markettop 36% Techtop 37% Moattop 37% Growthbottom 46% Globalbottom 39% Newsbottom 34% Funding: Raised $255M across 2 rounds · 2 rounds over 13 yrs (0.2/yr) Fin. health: Revenue ~$336M · Revenue +4% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $255M | 14 mo ago | 51 | — | DrupalApple iCloud MailMicrosoft 365+28 | — | — | 1 partnership |
| 3 | Opthea Developer of protein therapies for ophthalmology | $134M | 14 mo ago | 24 | Frederic Guerard Chief Executive Officer | DrupalPHPAmazon Web Services+21 | — | — | — |
| 4 | Bionomics Developing therapeutics for cancer and central nervous system disorders using proprietary drug discovery… | $108M | 24 mo ago | 7 | — | — | — | 436 patents Novel heterocyclic small‑molecule therapeutics for CNS disorders and pain relief | — |
| 5 | Aravax Developer of vaccine for peanut allergy | $93M | 28 mo ago | 2 | — | WordPressMySQLPHP+15 | — | — | — |
| 6 | Kazia Therapeutics Developer of small molecules for the treatment of cancer | $86M | 6 mo ago | 9 | — | ZURB FoundationMicrosoft ASP.NETAmazon Web Services+14 | — | 3 patents Novel functionalized benzopyran compounds for therapeutic drug development | 1 expansion · 1 award |
| 7 | SpeeDx Provider of qPCR-based molecular diagnostics platform | $78M | 39 mo ago | 113 | Alison Todd Co-Founder | WordPressMySQLPHP+41 | 4 signals ▼20% Announcements · Contracts · Capital raise | — | 5 partnerships |
| 8 | Benitec Biopharma Limited Developer of RNAi-based therapies for infectious, ocular, and genetic diseases | $71M | 25 mo ago | 18 | — | BootstrapApache HTTP ServerjQuery+10 | 5 signals ▼64% Announcements · Leadership · IPO | 120 patents Engineered AAV gene‑therapy vectors and OPMD therapeutic reagents for muscle disease treatment | 1 launch |
| 9 | Vaxxas Developer of a needle-free patch technology for vaccine delivery applications 57News top 17%Funding top 23%Growth top 25%Moat top 39% All 8 signals ▾Newstop 17% Fundingtop 23% Growthtop 25% Moattop 39% Talenttop 45% Markettop 50% Techbottom 36% Globalbottom 36% News: 11 BI events in 12 mo (of 30 tracked, 6 types) · +1000% YoY Funding: Raised $59.3M across 9 rounds · 9 rounds over 15 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $59M | 9 mo ago | 113 | David Peacock CEO | PHPBootstrapLiteSpeed+10 | 11 signals ▲1000% Leadership · Funding · Capital raise | — | — |
| 10 | Science In Sport Brand of sports nutrition and vitamin products | $48M | 22 mo ago | 215 | — | Cart FunctionalityMagentoApple iCloud Mail+33 | — | — | — |
| 11 | ImmVirX Developer of immunotherapy for cancer treatment | $47M | 36 mo ago | 16 | Malcolm McColl Co-Founder & CEO | — | — | — | — |
| 12 | Micro-X CNT based X-ray imaging systems | $47M | 5 mo ago | 109 | — | Webflow EcommerceWebflowGSAP+15 | — | 53 patents Advanced X-ray beamforming and high‑current field‑emitter imaging technologies | — |
| 13 | Radiopharm Theranostics Manufacturer of radiopharmaceutical products for diagnostic test | $46M | 22 mo ago | — | Paul Hopper Executive Chairman & Founder | WordPressMySQLPHP+21 | 4 signals Earnings · Leadership · Funding | — | — |
| 14 | Recce Developer of antibiotics for drug-resistant bacteria and cancer treatments | $41M | 12 mo ago | — | James Graham CEO | WordPressMySQLPHP+26 | — | 8 patents Antimicrobial polymer therapeutics for viral and bacterial infection treatment | 4 partnerships |
| 15 | PolyNovo Developer of biodegradable temporising matrix for treating traumatic wounds | $30M | 25 mo ago | 8 | — | WordPressApple iCloud MailMySQL+34 | — | — | — |
| 16 | Clarity Pharmaceuticals Developer of drugs to treat cancer | $28M | 10 mo ago | 41 | — | WordPress Block EditorwpBakeryWordPress+24 | — | 129 patents Targeted radiopharmaceuticals for prostate and neuroendocrine cancer imaging and therapy | — |
| 17 | OncoSil Medical Developer of a medical device for the treatment of pancreatic cancer | $28M | 12 mo ago | 2 | Daniel Kenny Chief Executive Officer | WordPressMySQLPHP+28 | — | 7 patents Patents concentrated in health & consumer products | 1 partnership |
| 18 | ProTA Therapeutics Developer of oral immunotherapies for treating food allergies | $26M | 29 mo ago | — | Mimi Tang Founder & CEO | — | — | 16 patents Formulation and delivery of allergy therapeutics (pharmaceutical compositions for allergic disease treatment) | — |
| 19 | CurveBeam AI Developer of AI-powered CT imaging solutions | $25M | 4 mo ago | 83 | Arun Singh CEO | WordPressSentryMySQL+41 | 3 signals Funding · Regulatory | 55 patents AI-driven medical imaging analysis: alignment correction, segmentation, material decomposition, abnormality detection. | — |
| 20 | Ena Respiratory Developer of antiviral host defense enhancers for respiratory infections. | $25M | 7 mo ago | 9 | Christophe Demaison Managing Director | — | — | 38 patents Lipid-based TLR2 agonist immunostimulants for treating respiratory infections and allergies | — |
| 21 | EMvision Provider of portable electromagnetic microwave imaging solution | $24M | 27 mo ago | — | Scott Kirkland CEO and Managing Director | WordPressMySQLPHP+26 | — | — | — |
| 22 | PolyActiva Drug delivery platform | $24M | 12 mo ago | 27 | — | — | — | — | — |
| 23 | Arovella Therapeutics Developer of cell therapies to treat cancer and neurological diseases | $23M | 17 mo ago | 44 | — | — | — | 2 patents Repurposing anagrelide for cancer therapy, especially metastatic thrombocytotic cancers | — |
| 24 | Chimeric Therapeutics Provider of CAR T cell therapies for solid tumors | $21M | 19 mo ago | 19 | Paul Hopper Executive Chairman & Founder | WixSentryBootstrap+13 | — | — | 1 award |
| 25 | Alterity Provider of therapies to treat neurodegenerative disease | $20M | 9 mo ago | 11 | David Stamler Chief Executive Officer | WordPressMySQLPHP+20 | — | — | — |
| 26 | Rage Biotech Developer of therapeutics for respiratory diseases | $19M | 7 mo ago | 6 | — | — | — | 22 patents Nucleic‑acid therapeutics targeting RAGE for respiratory disease treatment and monitoring | — |
| 27 | Noxopharm Developer of drugs for the treatment of cancer and septic shock | $18M | 26 mo ago | 17 | — | ZURB FoundationMicrosoft ASP.NETAmazon ALB+12 | — | 65 patents Isoflavone-derived pharmaceutical compounds for cancer immunotherapy and infection‑related inflammation | 2 launchs · 1 partnership |
| 28 | GPN Vaccines Developer of a vaccine against Streptococcus pneumonia | $18M | 5 mo ago | 24 | — | WordPressMySQLPHP+13 | — | 21 patents Streptococcal vaccine composition, formulation, and immunogenic protein engineering | — |
| 29 | AdvanCell Radiopharmaceutical company developing targeted alpha therapies for cancer treatment | $17M | 14 mo ago | 23 | Andrew Adamovich Founder | WordPressApple iCloud MailMySQL+12 | — | — | 1 expansion |
| 30 | Proteomics International Medical technology company at the forefront of predictive diagnostics and bio-analytical services | $16M | 28 mo ago | — | Richard Lipscombe Co-Founder & Managing Director | WordPressMySQLPHP+11 | — | — | — |
| 31 | Psylo Developer of psychedelic derived therapeutic for mental illness | $14M | 24 mo ago | 24 | Josh Ismin Co-Founder & CEO | — | — | — | — |
| 32 | OncoRes Medical Developer of intraoperative imaging technology for surgical procedures 45Patents top 29%Funding top 32%Moat top 32%Innovation top 34% All 8 signals ▾Patentstop 29% Fundingtop 32% Moattop 32% Innovationtop 34% Newstop 39% Techtop 45% Globalbottom 35% Marketbottom 34% Patents: 48 patents matched (strict assignee match) · 23 filings since 2022 vs 25 in 2017-21 Funding: Raised $13.9M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $14M | 4 mo ago | 31 | — | WixSentryEnvoy+15 | — | 48 patents Medical elastography and optical palpation devices for assessing tissue mechanical properties | 1 job opening · 1 partnership |
| 33 | Kinoxis Therapeutics Developer of therapies fort treating CNS disorders | $13M | 22 mo ago | 13 | Hugh Alsop Co-Founder & CEO | — | — | 66 patents Non‑peptide oxytocin receptor agonists for treating social and substance‑use disorders | — |
| 34 | Incannex Company developing proprietary medicinal cannabinoid drugs and psychedelic medicine therapies 40Funding top 34%Growth top 35%Tech top 44%Talent bottom 49% All 6 signals ▾Fundingtop 34% Growthtop 35% Techtop 44% Talentbottom 49% Marketbottom 29% Globalbottom 25% Funding: Raised $12.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $12M | 15 mo ago | — | Joel Latham CEO & MD | DrupalPHPAmazon Web Services+26 | — | — | — |
| 35 | Orthocell Developer of regenerative medicine for orthopedic diseases | $11M | 19 mo ago | — | Paul Anderson Founder & CEO | WordPressApple iCloud MailMicrosoft 365+28 | — | 94 patents Collagen-based regenerative implants and devices for soft tissue and nerve repair | — |
| 36 | Cartherics Developer of cellular immunotherapy for cancer | $10M | 20 mo ago | — | Ian Nisbet Co-Founder and Chief Operating Officer | WordPressCart FunctionalityMySQL+18 | — | — | 2 awards |
| 37 | Ferronova Provider of magnetic probe based device of treatment of multiple cancer | $9M | 6 mo ago | 10 | — | WordPressMySQLPHP+22 | — | — | — |
| 38 | Island Pharmaceuticals Developer of antiviral therapeutics for infectious diseases | $7M | 4 mo ago | — | David Foster Chief Executive Officer and Managing Director | ZURB FoundationMicrosoft ASP.NETCloudflare+13 | — | 2 patents Antiviral drug formulations targeting SARS‑CoV‑2 and polymerase inhibition. | — |
| 39 | All G Developer of animal-free proteins using precision fermentation for nutrition applications 21Funding top 43%Global top 45%Talent bottom 49%Tech bottom 44% All 5 signals ▾Fundingtop 43% Globaltop 45% Talentbottom 49% Techbottom 44% Marketbottom 25% Funding: Raised $6.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 3 countries beyond Australia rank vs industry peers · Fliar Intelligence Index 21/100 | $7M | 6 mo ago | — | Jan Pacas Co-Founder & CEO | WordPressMySQLPHP+27 | — | — | — |
| 40 | INOVIQ Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer | $6M | 8 mo ago | 5 | Leearne Hinch CEO | Cart FunctionalityZURB FoundationMicrosoft ASP.NET+20 | — | 4 patents Polymer resin formulations and extracellular vesicle-based therapeutic/diagnostic technologies. | 1 job opening |
| 41 | Australis Scientific Developing novel medical products that utilise neural modulation technologies | $6M | 0 mo ago | — | Danielle Delaney Co-Founder | — | — | — | 1 internship · 1 launch · 2 partnerships |
| 42 | Cambium Bio Developer of therapeutics for ophthalmology and tissue regeneration | $4M | 4 mo ago | — | Karolis Rosickas CEO | — | — | — | 1 partnership |
| 43 | Neurizon Therapeutics Developer of therapeutics for neurodegenerative diseases | $4M | 3 mo ago | — | Michael Thurn CEO & Managing Director | WordPressPleskMySQL+24 | — | — | — |
| 44 | Dignify Therapeutics Novel drug therapies for bladder and bowel disorders | $3M | 15 mo ago | 35 | — | — | — | — | — |
| 45 | Convergence Medical Developer of robots for arthroscopic surgery | $3M | 17 mo ago | 2 | — | — | — | 9 patents Robotic-assisted arthroscopic surgery hardware and control interfaces | — |
| 46 | Microba Developer of microbiome-based drug discovery platform | $3M | 11 mo ago | 72 | Gene Tyson Founder & Director | Cart FunctionalityWordPressBugHerd+32 | — | — | — |
| 47 | Imugene Developer of a therapeutic vaccine for the treatment of cancer | $2M | 17 mo ago | 5 | Leslie Chong CEO & MD | WordPressMySQLPHP+23 | — | 15 patents Therapeutic cancer vaccines and oncolytic virus platforms for immune activation | — |
| 48 | PredicTx Health Developer of a platform for personalized chemotherapy dosing using body analysis | $2M | 8 mo ago | — | Justin Yeung Co-Founder & CMO | — | — | — | — |
| 49 | H3D Provider of software to manufacturers and labs custom-fit businesses 37Tech top 28%Growth top 35%Funding top 46%Moat top 48% All 7 signals ▾Techtop 28% Growthtop 35% Fundingtop 46% Moattop 48% Talentbottom 49% Globalbottom 29% Marketbottom 23% Tech: 55 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Cloudflare Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $1M | 9 mo ago | 11 | Phil Kinsella Founder & CTO | WordPress Block EditorElementorWordPress+38 | — | — | 1 partnership |
| 50 | Argenica Therapeutics Developer of neuroprotective therapeutics for stroke and neural injuries | $971K | 11 mo ago | — | Liz Dallimore CEO & Managing Director | WordPressMySQLPHP+13 | — | 3 patents Neuroprotective peptide therapeutics for brain injury and neurodegeneration | 2 launchs · 1 partnership |
Top 12 Life Sciences companies in Australia
#1
Public · Sydney, New South Wales · founded 1994 · 9 employees$85.7Mraised▾
Developer of small molecules for the treatment of cancer. The lead product Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway which regulates growth and cell division is used for the treatment of glioblastoma, DIPG, CNS lymphoma, and brain metastases. Another drug VT801 is a small molecule inhibitor of VEGFR3, which helps in the development of new blood vessels and lymphatic vessels in a growing tumour.
- Dec 2025Post IPO$55.3M
- Aug 2025Post IPO$2.1M
- Jan 2023Post IPO$3.1M
- Oct 2020Post IPO$11.8M
#2
Public · Melbourne, Victoria · founded 2004 · 83 employees$979.8Mraised▾
Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL® HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low bac
- Jan 2025Post IPO$160M
- Apr 2023Post IPO—
- Aug 2022Post IPO$45M
- Mar 2021Post IPO$110M
#3
Public · Adelaide, South Australia · founded 2011 · 109 employees$46.7Mraised▾
Micro-X develops, manufactures and markets a variety of of ultra-lightweight, mobile x-ray imaging systems for medical and security applications. Its flagship product includes "NANO", a mobile X-ray system (Pending FDA 510(k) Clearance) for portable chest, ICU, orthopaedic and pediatric imaging. The company is also working on another product called as ROVER for use in military deployed medical facilities and Backscatter Imager system for stand-off imaging of Improvised Explosive Devices.
- Dec 2025Post IPO$6.2M
- Feb 2021Post IPO$30.5M
- May 2017Post IPO$10M
#4
Public · Melbourne, Victoria · founded 2009 · 83 employees$25.3Mraised▾
Developer of AI-powered CT imaging solutions. The company is developing AI-based weight-bearing CT (WBCT) imaging systems for the orthopedic and musculoskeletal (MSK) specialties for the diagnosis of lower extremity conditions.
- Feb 2026Post IPO$2.8M
- Feb 2023Series A$25M
- Nov 2022Seed$255.4K
#5
Series B · Perth, Western Australia · founded 2014 · 31 employees$13.9Mraised▾
Developer of intraoperative imaging technology for surgical procedures. The company utilizes a combination of optical coherence tomography imaging and elastography to provide a rapid evaluation of tissue microarchitecture at a scale and resolution comparable to histology. on the development of an imaging probe that will enable breast cancer surgeons to identify residual cancer following the excision of a tumor, providing a solution to address the high re-excision rates for breast cancer patients.
- Feb 2026Series B$19.2M
- Oct 2022Grant (prize money)$942.2K
- May 2022Grant (prize money)$3M
- May 2022Series A$9.5M
#6
Series A · Fortitude Valley, Queensland · founded 2021$6Mraised▾
Developing novel medical products that utilise neural modulation technologies. Its flagship product, the In Confidence Smart Patch, which aims to provide a discreet solution for both acute and chronic urinary incontinence symptoms.
- Nov 2025Series A$6M
- Oct 2023Seed—
#7
Series D · Brisbane, Queensland · founded 2010 · 113 employees$59.3Mraised▾
Developer of a needle-free patch technology for vaccine delivery applications. The company’s technology uses a patch with microprojections applied to the skin. This approach aims to enhance vaccine efficiency and effectiveness. The company’s dry-coating technology reduces the need for vaccine refrigeration during storage and transport. The company targets applications in infectious disease and oncology.
- Aug 2025Conventional Debt$25.2M
- Aug 2025Series D$31.9M
- Dec 2022Series C$23M
- Sep 2022Grant (prize money)$5.5M
#8
Novotech 🦄Acquired · Sydney, New South Wales · founded 2002 · 51 employees$255Mraised▾
Provider of clinical research services across all trial phases and therapeutic areas. It offers services including medical and regulatory consulting, patient recruitment, site selection, early phase trials, clinical operations, project management, site management, biometrics, data management, virtual clinical trials, real-world data analysis, and laboratory services. It also provides specialized services for oncology, pharmacometrics, drug development consulting, GMO solutions, liver disease, infectious diseases, vaccines, and orphan/rare diseases. It focuses on clinical and regulatory strategy to assist biotechnology companies in conducting early-phase clinical trials.
- Mar 2025Seed—
- Jan 2022Conventional Debt$505M
- Jan 2022PE$255M
- Feb 2021PE—
#9
Series B · Canberra, Australian Capital Territory · founded 2017 · 24 employees$18Mraised▾
Developer of a vaccine against Streptococcus pneumonia. The vaccine Gamma-PN is a whole-cell vaccine that is capable of inducing broad-spectrum T- and B-cell immunity. This is developed by using a gamma-irradiation process that inactivates and kills the vaccine strain but surface protein antigens are conserved and maintained during vaccine production that provides immunity.
- Dec 2025Series B$3.5M
- Jun 2024Series B$18M
#10
Series B · Melbourne, Victoria · founded 2020 · 9 employees$25Mraised▾
{}
- Oct 2025Series B$22.4M
- Feb 2025Series B$5M
- Jun 2021Series B$25M
#11
Public · South Yarra, Victoria · founded 1985 · 24 employees$133.7Mraised▾
Opthea develops and commercializes protein therapies for ophthalmology. Its approach includes targeting the Vascular Endothelial Growth Factor (VEGF) protein family, specifically VEGF-C, VEGF-D, and VEGFR-3. Its lead candidate, a soluble form of VEGF-3, is currently in phase I/IIA trials for the treatment of wet age-related macular degeneration.
- Mar 2025Post IPO—
- Aug 2022Post IPO$90.2M
- Oct 2019Conventional Debt$9.9M
- Apr 2017Post IPO$33.6M
#12
Public · Camberwell, Victoria · founded 2016$7.5Mraised▾
Developer of antiviral therapeutics for infectious diseases. The lead drug candidate ISLA-101 is repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases. It prevents nuclear entry of the viral protein that prevents propagation of the viral infection.
- Feb 2026Post IPO$6.3M
- Mar 2024Post IPO$1.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Australia
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 861 Australia-affiliated papers.
- University College London67
- The University of Queensland63
- The University of Melbourne59
- Agriculture and Food54
- La Trobe University35
- Mutant2→11
- Genome1→7
- Immune system1→5
- Antibody1→4
- Mitochondrion2→4
- Gene5→17
- Immune system2→13
- Antibody1→10
- Messenger RNA1→10
- Mutant1→9
- Agriculture5→19
- Sustainability3→8
- Emerging technologies1→4
- Resistance (ecology)3→6
- Bacteria2→5
Where biotechnology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.